Status

Pending July 2026 FDA review. The compounded form is restricted; FDA-approved as Vyleesi for HSDD in premenopausal women only. Compounded use is part of the PCAC re-evaluation slated for July 23–24, 2026.

Join waitlist →
Libido · Sexual health Rx · Prescription required

PT-141.

Bremelanotide · Central Libido

A melanocortin receptor agonist that acts on the brain's desire pathways, not the vasculature. Works upstream of the plumbing PDE-5 inhibitors target — for desire, not just arousal.

From $150 / month
MW 1025.2 Molecular weightThe mass of one molecule of bremelanotide in g/mol. A small, fully characterized cyclic peptide.
Sequence 7 aa Peptide chain length7 amino acids — a cyclic heptapeptide derivative of α-MSH (melanocyte-stimulating hormone).
Route Sub-Q How you take itSubcutaneous: under the skin. Same technique as a GLP-1 or insulin pen.
Cycle As needed Cycle lengthPT-141 is dosed as-needed before desired effect, not on a daily cycle. Onset 30–60 min, duration 6–12 hr.
Discovered 2000s First isolatedBremelanotide was developed in the early 2000s. FDA-approved as Vyleesi for HSDD in premenopausal women in 2019.
Begin your protocol Free assessment · No card · Rx required
PT-141 Libido
MW 1025.2 Length 7 aa Route Sub-Q Cycle As-needed
Begin →
01 The case

Desire, not just plumbing.

PT-141 acts in the hypothalamus, not in the corpus cavernosum. It binds the melanocortin 3 and 4 receptors — receptors involved in central sexual motivation. PDE-5 inhibitors (sildenafil, tadalafil) make blood flow easier; PT-141 changes whether you want it.

That distinction is what makes it useful for indications PDE-5 inhibitors miss: SSRI-related libido loss, hormonal libido loss, hypoactive sexual desire disorder. It also works for both sexes — Vyleesi is approved only for women, but the central mechanism doesn't care which body it's running on.

Onset is 30–60 minutes; duration 6–12 hours. There is no interaction with blood pressure medications, no vascular load. It is dosed as-needed, not daily.

02 Mechanism

Where it acts.

Six effects of one upstream binding event — melanocortin receptor agonism in the hypothalamus.

PT-141 C₅₀H₆₈N₁₄O₁₀
⌬ MC3R / MC4R Melanocortin receptor agonism in CNS
◐ Hypothalamic activation Central sexual-motivation circuits
∿ Sexual desire Acts on motivation, not arousal mechanics
⌒ Both sexes Mechanism is sex-independent
⊖ No vascular load Does not engage blood-pressure pathways
↗ PDE-5 compatible Stacks safely with sildenafil / tadalafil
03 Evidence

Approved, with asterisks.

Bremelanotide is FDA-approved as Vyleesi for premenopausal women with HSDD. Compounded off-label use is broader. The mechanism is the same.

30-60 min

typical onset to effect after sub-Q dose

Clinical pharmacology
6-12 hr

duration of effect after a single dose

Clinical pharmacology
Both sexes

central mechanism is sex-independent — Vyleesi label is women only

Receptor pharmacology
0

blood-pressure interaction — distinct from PDE-5 inhibitors

Safety profile
04 Who it's for

Built for desire.

Most often prescribed for indications where blood flow isn't the bottleneck — central, hormonal, or pharmacologic libido loss.

◐

HSDD

Hypoactive sexual desire disorder. The labeled use of Vyleesi.

⊖

SSRI libido loss

When the antidepressant is necessary but the libido cost isn't acceptable.

∿

Hormonal libido loss

Postpartum, perimenopause, low T — desire changes that aren't about plumbing.

⌒

Both sexes

Mechanism applies regardless of label.

↗

Vascular-independent

Useful when PDE-5 inhibitors are insufficient.

⚛

Adjunct to PDE-5

Can be combined where both axes need support.

05 Protocol

A sample protocol.

PT-141 is dosed as-needed, not on a daily cycle. Take it before the desired effect window — not as a maintenance medication.

Sample parameters

Illustrative
Route
Subcutaneous injection
Dose
0.5–2 mg
Frequency
As needed
Cycle
Occasional
Storage
Refrigerated, light-protected

As-needed only. PT-141 is not dosed daily. Wait at least 24 hours between doses. Compounded fresh by a 503A pharmacy to USP 797 sterile standards.

The cadence

Your week As-needed · not daily
M
T
W
T
F
S
S
Your cycle Use only when desired
1
2
3
4
5
6
7
8
As-needed dose ≥24 hr between doses
06 What arrives

In the box.

Compounded fresh, cold-chain shipped overnight from a U.S.-based 503A pharmacy. As-needed dosing — supply lasts longer than daily protocols.

⚲
Compounded vials

Multi-dose vial · USP 797 sterile · beyond-use date printed.

⊕
Injection supplies

Insulin syringes, alcohol pads, bacteriostatic water for reconstitution.

❄
Cold-pack shipping

Insulated overnight delivery with ice pack. Tracked door to door.

📖
Step-by-step guide

Reconstitution, dosing math, injection technique, sharps disposal.

07 Often paired with

Stacks that work.

PT-141 stands alone for its specific use. When stacked, it's usually with the underlying vitality stack.

Sermorelin

GH-axis support pairs with central libido — both contribute to overall vitality.

Vitality stackFrom $195/mo →
NAD+

Cellular energy availability complements desire-pathway activation.

Energy / libidoFrom $200/mo →
08 Safety

Side effects, fine print, responsibility.

PT-141 has a distinct safety profile. The most-reported effects are transient and dose-dependent.

✓

What to expect

  • 01Transient nausea — the most common report. Often resolves with lower starting dose.
  • 02Brief flushing or warmth — typically peaks 30–60 min post-injection.
  • 03Mild blood-pressure rise — small, transient — disclose any cardiovascular history.
  • 04No vascular dependency — distinct from PDE-5 inhibitors — works on a separate pathway.
!

Not for

  • 01Uncontrolled hypertension or cardiovascular disease. PT-141 can cause transient BP elevation.
  • 02Pregnancy or breastfeeding. Insufficient safety data outside the Vyleesi label.
  • 03Daily dosing. Not designed for daily use — wait ≥24 hr between doses.
  • 04Use without oversight. Always under a licensed physician's supervision.

Bremelanotide is FDA-approved as Vyleesi for HSDD in premenopausal women. Other compounded uses are off-label and dispensed by licensed 503A pharmacies under a prescription written by a U.S.-licensed physician for individual investigational and off-label use under provider supervision. Statements on this page have not been evaluated by the FDA for off-label use. Individual results vary.

09 Questions

Frequently asked.

What is PT-141?+

PT-141 (bremelanotide) is a cyclic 7-amino-acid peptide that activates melanocortin receptors in the hypothalamus. It addresses sexual desire centrally, distinct from PDE-5 inhibitors that act on vascular flow.

How is it different from sildenafil or tadalafil?+

PDE-5 inhibitors make blood flow easier — they help arousal. PT-141 acts in the brain on the desire pathways. They are complementary, not interchangeable.

Does it work for both sexes?+

Yes. The melanocortin mechanism is sex-independent. Vyleesi (the FDA-approved formulation) is labeled only for premenopausal women with HSDD, but the mechanism applies more broadly. Compounded use is off-label.

How quickly does it work?+

Onset is 30–60 minutes after sub-Q injection. Duration is 6–12 hours. Plan dosing accordingly — it is not an instant-acting medication.

Is it daily?+

No. PT-141 is as-needed only. Wait at least 24 hours between doses. Daily dosing is not the protocol.

Side effects?+

Transient nausea is most common. Brief flushing and a small, transient BP rise are reported. Disclose any cardiovascular history during intake.

Begin Ten minutes of intake

Begin your PT-141 protocol.

Free assessment. A board-certified U.S. physician on the prescription. Bloodwork only if your protocol calls for it. Compounded fresh and cold-chain shipped overnight.

Start your intake Free · No card required · Rx required to ship

Other compounds in the roster.

All 8 therapies →
Sermorelin

GHRH analog. Sleep depth, lean mass, recovery — pulses your own GH at night.

From $195/mo NAD+

Cellular energy coenzyme. Sirtuins, DNA repair, mitochondrial output. The longevity substrate.

From $200/mo

Deeper guides on PT-141.

All guides →